Sinopharm offers to take China-TCM private in nearly $3 bln deal
Sinopharm, the parent of China Traditional Chinese Medicine Holdings, has revived a take-private bid for the Hong-Kong-listed drugmaker, valuing it at HK$23.16 billion , the companies said...